News | May 08, 2009

Positron Systems, ISU to Produce Nuclear Medicine Isotope

May 8, 2009 - Positron Systems Inc. signed a Letter of Intent with Idaho State University (ISU) that will set the stage in a public/private partnership for the production and distribution of molybdenum-99 (99Mo), a widely used isotope in nuclear medicine.

The U.S. supply of 99Mo is not secure due to its reliance on a foreign supplier and safety concerns arising from the nuclear reactor-based production method currently employed by all current suppliers. Scientists at ISU’s Idaho Accelerator Center have developed a novel, proprietary method to produce 99Mo and are currently engaged in additional 99Mo research.
Worldwide production and sale of 99Mo is estimated to be a multi-billion a year industry.

“Idaho State University is on a trajectory to become a national leader in medical isotope research and development,” said ISU Vice President for Research, Dr. Pam Crowell. “We are excited to work toward a partnership with Positron Systems, an Idaho-based company, to help deliver vital medical products to the U.S.”

T. Erik Oaas, Chairman of Positron Systems, said, “Working side-by-side with ISU, we intend to replace the foreign supply of 99Mo in the U. S. with a product produced here in Idaho.” Positron Systems has facilities in Boise and Pocatello, Idaho.

ISU recently received nearly $1 million in federal appropriation to further their 99Mo research efforts.

For more information: www.positronsystems.com and www.isu.edu

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init